Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

O. Schnell, T. Battelino, R. Bergenstal, AL. Birkenfeld, A. Ceriello, A. Cheng, M. Davies, S. Edelman, T. Forst, F. Giorgino, J. Green, PH. Groop, S. Hadjadj, H. J L Heerspink, M. Hompesch, B. Izthak, L. Ji, N. Kanumilli, B. Mankovsky, C....

. 2023 ; 22 (1) : 59. [pub] 20230316

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu dopisy

Perzistentní odkaz   https://www.medvik.cz/link/bmc23003791

The 8th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Kidney, and Glycemic Outcomes was held virtually on November 10-12, 2022. Following the tradition of previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed outcomes trials as well as key trials important to the cardiovascular (CV) field. This year's focus was on the results of the DELIVER, EMPA-KIDNEY and SURMOUNT-1 trials and their implications for the treatment of heart failure (HF) and chronic kidney disease (CKD) with sodium-glucose cotransporter-2 (SGLT2) inhibitors and obesity with glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. A broad audience of primary care physicians, diabetologists, endocrinologists, cardiologists, and nephrologists participated online in discussions on new consensus recommendations and guideline updates on type 2 diabetes (T2D) and CKD management, overcoming clinical inertia, glycemic markers, continuous glucose monitoring (CGM), novel insulin preparations, combination therapy, and reclassification of T2D. The impact of cardiovascular outcomes on the design of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) trials, as well as the impact of real-world evidence (RWE) studies on the confirmation of CVOT outcomes and clinical trial design, were also intensively discussed. The 9th Cardiovascular Outcome Trial Summit will be held virtually on November 23-24, 2023 ( http://www.cvot.org ).

3rd Medical Department and Laboratory for Endocrinology and Metabolism 1st Faculty of Medicine Charles University Prague Czech Republic

Altman Clinical and Translational Research Institute La Jolla CA USA

Cardiovascular division Brigham and Women's Hospital Boston MA USA

Center for Diabetes Research Gentofte Hospital University of Copenhagen Hellerup Denmark

Center Internal Medicine Fünf Höfe Munich Germany

Clalit Health Services and Technion Faculty of Medicine Haifa Israel

Credit Valley Hospital Mississauga ON Canada

CRS Clinical Research Services Mannheim GmbH Mannheim Germany

Department of Clinical Medicine University of Copenhagen Copenhagen Denmark

Department of Clinical Pharmacy and Pharmacology University Medical Center Groningen University of Groningen Groningen The Netherlands

Department of Diabetes Central Medical School Monash University Melbourne Australia

Department of Endocrinology Catholic University Leuven Leuven Belgium

Department of Family Medicine Acıbadem Mehmet Ali Aydınlar University School of Medicine Istanbul Turkey

Department of Internal Medicine 4 University Clinic Tübingen Tübingen Germany

Department of Medicine K2 Karolinska Institute Stockholm Sweden

Department of Nephrology University of Helsinki and Helsinki University Hospital Helsinki Finland

Department of Precision and Regenerative Medicine and Ionian Area University of Bari Aldo Moro Bari Italy

Diabetes Division St Josef Hospital Ruhr University Bochum Bochum Germany

Diabetes Research Centre University of Leicester Leicester UK

Division of Endocrinology Department of Medicine and Duke Clinical Research Institute Duke University School of Medicine Durham NC USA

Division of Nephrology and Hypertension Medical Center University of Kansas Kansas City KS USA

Eli Lilly and Company Indianapolis IN USA

Endocrine and Metabolic Consultants Rockville MD USA

Faculty of Medicine University of Ljubljana Ljubljana Slovenia

Folkhälsan Institute of Genetics Folkhälsan Research Center Biomedicum Helsinki University of Helsinki Helsinki Finland

Forschergruppe Diabetes e 5 Helmholtz Center Munich Ingolstaedter Landstraße 1 Neuherberg 85764 Germany

German Center for Diabetes Research Tübingen Germany

Institute for Diabetes Research and Metabolic Diseases at the Eberhard Karls University of Tübingen Tübingen Germany

Institute of Life Course and Medical Sciences University of Liverpool Liverpool UK

International Diabetes Center at Park Nicollet Health Partners Minneapolis MN USA

IRCCS MultiMedica Milan Italy

Manchester University Foundation Trust Manchester UK

NIHR Biomedical Research Centre Leicester UK

Peking University People's Hospital Xicheng District Beijing China

Pontifical Catholic University of Paraná Curitiba Brazil

ProSciento Inc San Diego CA USA

Sciarc GmbH Baierbrunn Germany

Shupyk National Medical Academy of Postgraduate Education Kiev Ukraine

Steno Diabetes Center Copenhagen Herlev Denmark

Taking Control of Your Diabetes Solana Beach CA USA

Thorax Institute University Hospital of Nantes Nantes France

University Children's Hospital Ljubljana Slovenia

University Medical Center Ljubljana Slovenia

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003791
003      
CZ-PrNML
005      
20230425140903.0
007      
ta
008      
230418s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12933-023-01788-6 $2 doi
035    __
$a (PubMed)36927451
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Schnell, Oliver $u Forschergruppe Diabetes e. V., Helmholtz Center Munich, Ingolstaedter Landstraße 1, Neuherberg, 85764, (Munich), Germany. oliver.schnell@lrz.uni-muenchen.de
245    10
$a CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes / $c O. Schnell, T. Battelino, R. Bergenstal, AL. Birkenfeld, A. Ceriello, A. Cheng, M. Davies, S. Edelman, T. Forst, F. Giorgino, J. Green, PH. Groop, S. Hadjadj, H. J L Heerspink, M. Hompesch, B. Izthak, L. Ji, N. Kanumilli, B. Mankovsky, C. Mathieu, M. Miszon, R. Mustafa, M. Nauck, R. Pecoits-Filho, J. Pettus, K. Ranta, HW. Rodbard, P. Rossing, L. Ryden, PM. Schumm-Draeger, SD. Solomon, J. Škrha, P. Topsever, T. Vilsbøll, J. Wilding, E. Standl
520    9_
$a The 8th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Kidney, and Glycemic Outcomes was held virtually on November 10-12, 2022. Following the tradition of previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed outcomes trials as well as key trials important to the cardiovascular (CV) field. This year's focus was on the results of the DELIVER, EMPA-KIDNEY and SURMOUNT-1 trials and their implications for the treatment of heart failure (HF) and chronic kidney disease (CKD) with sodium-glucose cotransporter-2 (SGLT2) inhibitors and obesity with glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. A broad audience of primary care physicians, diabetologists, endocrinologists, cardiologists, and nephrologists participated online in discussions on new consensus recommendations and guideline updates on type 2 diabetes (T2D) and CKD management, overcoming clinical inertia, glycemic markers, continuous glucose monitoring (CGM), novel insulin preparations, combination therapy, and reclassification of T2D. The impact of cardiovascular outcomes on the design of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) trials, as well as the impact of real-world evidence (RWE) studies on the confirmation of CVOT outcomes and clinical trial design, were also intensively discussed. The 9th Cardiovascular Outcome Trial Summit will be held virtually on November 23-24, 2023 ( http://www.cvot.org ).
650    _2
$a lidé $7 D006801
650    _2
$a krevní glukóza $7 D001786
650    _2
$a selfmonitoring glykemie $7 D015190
650    12
$a kardiovaskulární nemoci $x diagnóza $x farmakoterapie $x epidemiologie $7 D002318
650    12
$a diabetes mellitus 2. typu $x diagnóza $x farmakoterapie $x epidemiologie $7 D003924
650    _2
$a receptor pro glukagonu podobný peptid 1 $x agonisté $7 D000067757
650    _2
$a hypoglykemika $x terapeutické užití $7 D007004
650    _2
$a ledviny $7 D007668
650    12
$a chronická renální insuficience $x diagnóza $x farmakoterapie $x epidemiologie $7 D051436
655    _2
$a dopisy $7 D016422
700    1_
$a Battelino, Tadej $u University Medical Center, Ljubljana, Slovenia $u University Children's Hospital, Ljubljana, Slovenia $u Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
700    1_
$a Bergenstal, Richard $u International Diabetes Center at Park Nicollet, Health Partners, Minneapolis, MN, USA
700    1_
$a Birkenfeld, Andreas L $u Department of Internal Medicine IV, University Clinic Tübingen, Tübingen, Germany $u Institute for Diabetes Research and Metabolic Diseases at the Eberhard-Karls-University of Tübingen, Tübingen, Germany $u German Center for Diabetes Research (DZD e.V.), Tübingen, Germany
700    1_
$a Ceriello, Antonio $u IRCCS MultiMedica, Milan, Italy
700    1_
$a Cheng, Alice $u Credit Valley Hospital, Mississauga, ON, Canada
700    1_
$a Davies, Melanie $u Diabetes Research Centre, University of Leicester, Leicester, UK $u NIHR Biomedical Research Centre, Leicester, UK
700    1_
$a Edelman, Steve $u Taking Control of Your Diabetes, Solana Beach, CA, USA
700    1_
$a Forst, Thomas $u CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
700    1_
$a Giorgino, Francesco $u Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, Bari, Italy
700    1_
$a Green, Jennifer $u Division of Endocrinology, Department of Medicine and Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA
700    1_
$a Groop, Per-Henrik $u Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland $u Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland $u Department of Diabetes, Central Medical School, Monash University, Melbourne, Australia
700    1_
$a Hadjadj, Samy $u Thorax Institute, University Hospital of Nantes, Nantes, France
700    1_
$a J L Heerspink, Hiddo $u Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
700    1_
$a Hompesch, Marcus $u ProSciento Inc., San Diego, CA, USA
700    1_
$a Izthak, Baruch $u Clalit Health Services and Technion Faculty of Medicine, Haifa, Israel
700    1_
$a Ji, Linong $u Peking University People's Hospital, Xicheng District, Beijing, China
700    1_
$a Kanumilli, Naresh $u Manchester University Foundation Trust, Manchester, UK
700    1_
$a Mankovsky, Boris $u Shupyk National Medical Academy of Postgraduate Education, Kiev, Ukraine
700    1_
$a Mathieu, Chantal $u Department of Endocrinology, Catholic University Leuven, Leuven, Belgium
700    1_
$a Miszon, Martin $u Sciarc GmbH, Baierbrunn, Germany
700    1_
$a Mustafa, Reem $u Division of Nephrology and Hypertension, Medical Center, University of Kansas, Kansas City, KS, USA
700    1_
$a Nauck, Michael $u Diabetes Division, St. Josef Hospital, Ruhr-University Bochum, Bochum, Germany
700    1_
$a Pecoits-Filho, Roberto $u Pontifical Catholic University of Paraná, Curitiba, Brazil
700    1_
$a Pettus, Jeremy $u Altman Clinical and Translational Research Institute (ACTRI), La Jolla, CA, USA
700    1_
$a Ranta, Kari $u Eli Lilly and Company, Indianapolis, IN, USA
700    1_
$a Rodbard, Helena W $u Endocrine and Metabolic Consultants, Rockville, MD, USA
700    1_
$a Rossing, Peter $u Steno Diabetes Center Copenhagen, Herlev, Denmark $u Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
700    1_
$a Ryden, Lars $u Department of Medicine K2, Karolinska Institute, Stockholm, Sweden
700    1_
$a Schumm-Draeger, Petra-Maria $u Center Internal Medicine Fünf Höfe, Munich, Germany
700    1_
$a Solomon, Scott D $u Cardiovascular division, Brigham and Women's Hospital, Boston, MA, USA
700    1_
$a Škrha, Jan $u Third Medical Department and Laboratory for Endocrinology and Metabolism, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Topsever, Pinar $u Department of Family Medicine, Acıbadem Mehmet Ali Aydınlar University School of Medicine, Istanbul, Turkey
700    1_
$a Vilsbøll, Tina $u Steno Diabetes Center Copenhagen, Herlev, Denmark $u Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
700    1_
$a Wilding, John $u Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK
700    1_
$a Standl, Eberhard $u Forschergruppe Diabetes e. V., Helmholtz Center Munich, Ingolstaedter Landstraße 1, Neuherberg, 85764, (Munich), Germany
773    0_
$w MED00008211 $t Cardiovascular diabetology $x 1475-2840 $g Roč. 22, č. 1 (2023), s. 59
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36927451 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425140859 $b ABA008
999    __
$a ok $b bmc $g 1924453 $s 1190000
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 22 $c 1 $d 59 $e 20230316 $i 1475-2840 $m Cardiovascular diabetology $n Cardiovasc Diabetol $x MED00008211
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace